Subscribe to our Newsletters !!


    Oncomine Precision Assay receives breakthrough Apparatus designation from the U.S FDA

    Thermo Fisher recently expanded its strategic partnership arrangement with Agios Pharmaceuticals into co-develop the company diagnostic (CDx) to get vorasidenib, an investigational, oral, brain-penetrant, double inhibitor of mutant IDH1 and IDH2 enzymes now under examination at the Stage 3 INDIGO research for IDH mutant LGG. As time passes, Thermo Fisher attempts to get premarket approval